GlycoMimetics Inc (GLYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlycoMimetics Inc (GLYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH141235D
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that research, develops and commercializes small molecule drugs. The company's products comprise rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis of sickle cell disease and blood cancers. It also provides GMI-1271, galectin inhibitors, GMI - 1359, GMI-1051 and research programs. GlycoMimetics designs and tests viral and bacterial entry inhibitors dendritic cell receptor. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

GlycoMimetics Inc (GLYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11

Equity Offering 12

GlycoMimetics Prices Public Offering of Shares for USD119 Million 12

GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14

GlycoMimetics Raises USD21 Million in Public Offering of Shares 16

GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18

GlycoMimetics Completes IPO For USD 64.4 Million 19

GlycoMimetics Inc - Key Competitors 21

GlycoMimetics Inc - Key Employees 22

GlycoMimetics Inc - Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Aug 09, 2018: Glycomimetics reports second quarter 2018 results and highlights recent company achievements 24

May 03, 2018: GlycoMimetics Reports First Quarter 2018 Results 25

Mar 06, 2018: GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results 26

Nov 08, 2017: GlycoMimetics Reports Program Updates and Third Quarter 2017 Results 27

Aug 03, 2017: GlycoMimetics Reports Program Updates and Second Quarter 2017 Results 29

May 08, 2017: GlycoMimetics Reports Program Updates and First Quarter 2017 Results 31

Mar 01, 2017: GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results 32

Corporate Communications 33

Jun 12, 2017: GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors 33

Mar 13, 2017: GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors 34

Product News 35

06/05/2017: GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting 35

05/17/2017: GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia 36

Product Approvals 37

May 25, 2017: GlycoMimetics' GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia 37

Clinical Trials 38

May 30, 2018: GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy 38

Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1271 at AACR Annual Meeting 2018 39

Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1359 at AACR Annual Meeting 2018 40

Mar 05, 2018: GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML 41

Feb 08, 2018: GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Chemotherapy 42

Dec 12, 2017: GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 43

Nov 01, 2017: GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting 44

May 18, 2017: GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML 46

May 02, 2017: GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma 48

Apr 20, 2017: GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting 49

Mar 07, 2017: GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 50

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1271 at AACR Annual Meeting 2017 51

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GlycoMimetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11

GlycoMimetics Prices Public Offering of Shares for USD119 Million 12

GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14

GlycoMimetics Raises USD21 Million in Public Offering of Shares 16

GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18

GlycoMimetics Completes IPO For USD 64.4 Million 19

GlycoMimetics Inc, Key Competitors 21

GlycoMimetics Inc, Key Employees 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

GlycoMimetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 18130
Site License
USD 500 INR 36260
Corporate User License
USD 750 INR 54390

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com